EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes

Renée Maria Saliby, Chris Labaki, Tejas R Jammihal, Wanling Xie, Maxine Sun, Valisha Shah, Eddy Saad, M Harry Kane, Soki Kashima, Katherine Sadak, Talal El Zarif, Deepak Poduval und 12 weitere

Cancer Cell · 2024-05 · 42 (5) · 732-735

DOI: 10.1016/j.ccell.2024.03.002 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Cancer Cell, 2024-05. Verfasst von Renée Maria Saliby und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center of Molecular and Cellular Oncology (CMCO), Yale University, New…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Saliby et al. show that a machine learning approach can accurately classify clear cell renal cell carcinoma (RCC) into distinct molecular subtypes using transcriptomic data. When applied to tumors biospecimens from the JAVELIN Renal 101 (JR101) trial, a benefit is observed with immune checkpoint inhibitor (ICI)-based therapy across all molecular subtypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsImmunotherapyImmune Checkpoint InhibitorsHumansMolecular Targeted TherapyTreatment OutcomeMachine Learning

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center of Molecular and Cellular Oncology (CMCO), Yale University, New Haven, CT, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Center of Molecular and Cellular Oncology (CMCO), Yale University, New Haven, CT, USA.

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • NIDDK NIH HHS

Zitieren

APA

Saliby, R. M., Labaki, C., Jammihal, T. R., Xie, W., Sun, M., Shah, V., Saad, E., Kane, M. H., Kashima, S., Sadak, K., El Zarif, T., Poduval, D., Motzer, R. J., Powles, T., Rini, B. I., Albiges, L., Pal, S. K., McGregor, B. A., McKay, R. R., …, & Braun, D. A. (2024). Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell, 42(5), 732-735. https://doi.org/10.1016/j.ccell.2024.03.002

Vancouver

Saliby RM, Labaki C, Jammihal TR, Xie W, Sun M, Shah V, et al. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell. 2024;42(5):732-735. doi:10.1016/j.ccell.2024.03.002

BibTeX
@article{Saliby2024,
  author = {Saliby, Renée Maria and Labaki, Chris and Jammihal, Tejas R and Xie, Wanling and Sun, Maxine and Shah, Valisha and Saad, Eddy and Kane, M Harry and Kashima, Soki and Sadak, Katherine and El Zarif, Talal and Poduval, Deepak and Motzer, Robert J and Powles, Thomas and Rini, Brian I and Albiges, Laurence and Pal, Sumanta K and McGregor, Bradley A and McKay, Rana R and Signoretti, Sabina and Van Allen, Eliezer M and Shukla, Sachet A and Choueiri, Toni K and Braun, David A},
  title = {Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {5},
  pages = {732--735},
  doi = {10.1016/j.ccell.2024.03.002}
}
Kostenlos starten →